Related Experiment Video

Updated: May 11, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases

Johannes Rudolph1

  • 1Department of Biochemistry, Duke University Medical Center, BOX 3813, LSRC Building, Room C125, Durham, North Carolina 27710, USA. johannes@alum.mit.edu

Nature Reviews. Cancer
|February 9, 2007
PubMed

Insights

Targeting transient protein interactions for cancer therapy is challenging. This review explores difficulties using cell division cycle 25 (Cdc25) phosphatases and cyclin-dependent kinase (CDK) substrates as examples.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Transient protein-protein interactions regulate critical cellular processes, including the cell cycle.
  • Dysregulation of these interactions is frequently observed in cancerous growth.
  • Developing drugs that target these dynamic interactions presents significant challenges.

Purpose of the Study:

  • To review the challenges and difficulties in targeting transient protein-protein interactions for anticancer drug development.
  • To use the cell division cycle 25 (Cdc25) phosphatases and their cyclin-dependent kinase (CDK)-cyclin substrates as a case study.

Main Methods:

  • Literature review of transient protein-protein interactions in cancer.
  • Analysis of the Cdc25 phosphatases and CDK-cyclin interactions.
  • Discussion of therapeutic targeting strategies and their limitations.

Main Results:

  • Transient interactions are crucial but difficult to target therapeutically.
  • The Cdc25-CDK-cyclin system exemplifies the complexities involved.
  • Current drug development strategies face hurdles in modulating these dynamic interactions.

Conclusions:

  • Targeting transient protein-protein interactions remains a promising but complex area for anticancer drug discovery.
  • Further research is needed to overcome the inherent difficulties in developing effective therapeutics.
  • The Cdc25 and CDK-cyclin systems highlight the need for innovative approaches in drug design.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...